**Editor**

Josef S Smolen

**Associate Editors**

Francis Berenbaum  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Kimme Hyrich  
Rik Lories  
Iain McInnes  
Thomas Pap  
David Pisetsky  
Désirée van der Heijde  
Kazuhiko Yamamoto

**Editorial office**

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 3655 5889  
E: [ard@bmj.com](mailto:ard@bmj.com)  
Twitter: @ARD\_BMJ  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)

**Disclaimer:** The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

**Copyright:** © 2021 BMJ Publishing Group Ltd and European Alliance of Associations for Rheumatology. All rights reserved; no part of this publication may be reproduced in any form without permission.

*ARD* is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases*, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

**Viewpoint**

- 961** Primary and secondary non-response: in need of operational definitions in observational studies  
*E Vallejo-Yagüe, E C Keystone, S Kandhasamy, R Micheroli, A Finckh, A M Burden*

**Rheumatoid arthritis**

- 965** Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial  
*V Stouten, R Westhovens, S Pazmino, D De Cock, K Van der Elst, J Joly, D Bertrand, P Verschueren*
- 974** Tenosynovitis has a high sensitivity for early ACPA-positive and ACPA-negative RA: a large cross-sectional MRI study  
*X M E Mathijssen, F Wouters, N Sidhu, E Niemanisverdriet, A van der Helm-van Mil*
- 981** Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial  
*H So, I T Cheng, S-L Lau, E Chow, T Lam, V W Hung, E K Li, J F Griffith, V W Lee, L Shi, J Huang, K Y Kwok, C-W Yim, T K Li, V Lo, J Lee, J J-W Lee, L Qin, L-S Tam*

- 989** Circulating blood metabolite trajectories and risk of rheumatoid arthritis among military personnel in the Department of Defense Biorepository  
*K H Costenbader, M DiIorio, S H Chu, J Cui, J A Sparks, B Lu, L Moss, L Kelmenson, M Feser, J Edison, C Clish, J Lasky-Su, K D Deane, E W Karlson*
- 997** Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020  
*W Xie, H Huang, G Li, Y Hao, Y Gui, Y Wang, X Deng, J Zhao, Y Geng, L Ji, X Zhang, Z Song, Z Zhang*

**Spondyloarthritis**

- 1004** Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study  
*A Deodhar, P Sliwinska-Stanczyk, H Xu, X Baraliakos, L S Gensler, D Fleishaker, L Wang, J Wu, S Menon, C Wang, O Dina, L Fallon, K S Kanik, D van der Heijde*

- 1014** Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial  
*J C-C Wei, T-H Kim, M Kishimoto, N Ogusu, H Jeong, S Kobayashi, 4827-006 study group*

- 1022** Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)  
*R BM Landewé, L S Gensler, D Poddubnyy, P Rahman, M Hojnik, X Li, S Liu Leage, D Adams, H Carlier, F Van den Bosch, on behalf of the COAST-Y study group*

**Sjögren's syndrome**

- 1031** Lysosome-associated membrane protein 3 misexpression in salivary glands induces a Sjögren's syndrome-like phenotype in mice  
*H Nakamura, T Tanaka, T Pranzatelli, Y Ji, H Yin, P Perez, S A Afione, S-I Jang, C Goldsmith, C Y Zheng, W D Swain, B M Warner, N Hirata, M Noguchi, T Atsumi, J A Chiorini*

**Systemic sclerosis**

- 1040** Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes  
*M Acosta-Herrera, M Kerick, E López-Isac, S Assassi, L Beretta, C P Simeón-Aznar, N Ortego-Centeno, International SSc Group, S M Proudman, Australian Scleroderma Interest Group (ASIG), N Hunzelmann, G Moroncini, J K de Vries-Bouwstra, G Orozco, A Barton, A L Herrick, C Terao, Y Allanore, M A Brown, T RDJ Radstake, C Fonseca, C P Denton, M D Mayes, J Martin*

MORE CONTENTS ►

Member since 2008  
JM00004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics  
<http://publicationethics.org/>



When you have finished with this please recycle it

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals open access scheme.  
See <http://authors.bmj.com/open-access/>


- 1048** X-linked inhibitor of apoptosis protein (XIAP) inhibition in systemic sclerosis (SSc)  
*C Bergmann, L Hallenberger, S Chenguiti Fakhouri, B Merlevede, A Brandt, C Dees, H Zhu, A Zehender, X Zhou, A Schwab, C-W Chen, A H Györfi, A E Matei, D Chakraborty, T Trinh-Minh, S Rauber, R Coras, A Bozec, A Kreuter, M Ziemer, G Schett, J H W Distler*

## Autoinflammatory disorders

- 1057** Pathogenic *UBA1* variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis  
*N Tsuchida, Y Kunishita, Y Uchiyama, Y Kirino, M Enaka, Y Yamaguchi, M Taguri, S Yamanaka, K Takase-Minegishi, R Yoshimi, S Fujii, H Nakajima, N Matsumoto*

## Osteoarthritis


- 1062** Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study  
 OPEN ACCESS  
*F Eckstein, M C Hochberg, H Guehring, F Moreau, V Ona, A R Bihlet, I Byrjalsen, J R Andersen, B Daelken, O Guenther, C Ladel, M Michaelis, P G Conaghan*

- 1070** Linking chondrocyte and synovial transcriptional profile to clinical phenotype in osteoarthritis  
 OPEN ACCESS  
*J Steinberg, L Southam, A Fontalis, M J Clark, R L Jayasuriya, D Swift, K M Shah, R A Brooks, A W McCaskie, J M Wilkinson, E Zeggini*

## Miscellaneous

- 1075** Novel self-amplificatory loop between T cells and tenocytes as a driver of chronicity in tendon disease  
 OPEN ACCESS  
*E Garcia-Melchor, G Cafaro, L MacDonald, L A N Crowe, S Sood, M McLean, U G Fazzi, I B McInnes, M Akbar, N L Millar*

## Epidemiology

- 1086** Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study  
 OPEN ACCESS  
*H Bower, T Frisell, D Di Giuseppe, B Delcoigne, G-M Ahlenius, E Baecklund, K Chatzidionysiou, N Feltelius, H Forsblad-d'Elia, A Kastbom, L Klareskog, E Lindqvist, U Lindström, C Turesson, C Sjöwall, J Askeling, The ARTIS Study Group*

## Letters

- 1095** Patient research partner involvement in rheumatology clinical trials: analysis of journal articles 2016–2020  
*H Wang, S Stewart, B Darlow, B Horgan, G Hosie, J Clark, N Dalbeth*
- 1096** Onset of rheumatoid arthritis after COVID-19: coincidence or connected?  
*V F A M Derksen, T Kissel, F B G Lamers-Karnebeek, A E van der Bijl, A C Venhuizen, T W J Huizinga, R E M Toes, A H E Roukens, D van der Woude*
- 1098** Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases  
*B J Boyarsky, J A Ruddy, C M Connolly, M T Ou, W A Werbel, J M Garonzik-Wang, D L Segev, J J Paik*
- 1100** Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases  
*C M Connolly, J A Ruddy, B J Boyarsky, R K Avery, W A Werbel, D L Segev, J Garonzik-Wang, J J Paik*
- 1101** SARS-CoV-2 infection among inpatients with systemic lupus erythematosus in France: a nationwide epidemiological study  
*A Mageau, G Aldebert, D Van Gysel, T Papo, J-F Timsit, K Sacre*
- 1102** Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab  
*M A Friedman, K L Winthrop*

## Electronic pages

- e122** New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS  
*F Assan, R Seror, X Mariette, G Nocturne*
- e123** Response to: 'New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS' by Assan *et al*  
*M Aringer, K Costenbader, T Dörner, S R Johnson*
- e124** Role of ANA testing in the classification of patients with systemic lupus erythematosus  
*D S Pisetsky, D M Spencer, B Rovin, P E Lipsky*
- e125** Response to: 'Role of ANA testing in the classification of patients with systemic lupus erythematosus' by Pisetsky *et al*  
*M Aringer, K H Costenbader, T Dörner, S R Johnson*

- e126** Do the 2019 EULAR/ACR SLE classification criteria close the door on certain groups of SLE patients?  
*H Chi, J Teng, Z Wang, C Yang, Y Su*
- e127** Response to: 'Do the 2019 EULAR/ACR SLE classification criteria close the door on certain groups of SLE patients?' by Chi *et al*  
*M Aringer, K H Costenbader, T Dörner, S R Johnson*
- e128** Titre-specific positive predictive value of antinuclear antibody patterns  
*J-B Vulsteke, L Van Hoovels, P Willems, B Vander Cruyssen, S Vanderschueren, R Westhovens, D Blockmans, E De Langhe, X Bossuyt*
- e129** Response to 'Titre-specific positive predictive value of anti-nuclear antibody patterns' by Vulsteke *et al*  
*J Damoiseaux, L E C Andrade, M J Fritzler, M Herold, M Infantino, C von Muhlen*
- e130** Circulating regulatory T cells were absolutely decreased in dermatomyositis/polymyositis patients and restored by low-dose IL-2  
*S-X Zhang, J Wang, H-H Sun, J-Q Zhang, G-Y Liu, J Luo, P-F He, X-F Li*
- e131** Response to: 'Circulating regulatory T cells were absolutely decreased in dermatomyositis/polymyositis patients and restored by low-dose IL-2' by Zhang *et al*  
*D Klatzmann*
- e132** Standardisation of myositis-specific antibodies: where are we today?  
*M Mahler, J-B Vulsteke, X Bossuyt, E De Langhe, M Satoh*
- e133** What is the starting dose of steroid prescribed by rheumatologist in the management of polymyalgia rheumatica?  
*J J Dubost, B Pereira, A Fan, M Soubrier*
- e134** Diabetes mellitus in ankylosing spondylitis  
*K-F Liao, Y-H Kuo, S-W Lai*
- e135** Response to: 'Diabetes mellitus in ankylosing spondylitis' by Liao *et al*  
*S Mathieu, M Soubrier*
- e136** Association between ankylosing spondylitis and venous thromboembolism  
*S-W Lai*
- e137** Risk of gout flares after vaccination  
*S-W Lai, Y-H Kuo, K-F Liao*
- e138** 'DESIRABLE' or not?  
*N Acharya, A Chattopadhyay, V Dhir*
- e139** Retraction: Dominant B cell receptor clones in peripheral blood predict onset of arthritis in individuals at risk for rheumatoid arthritis